BCL2 genotypes and prostate cancer survival
| Autor: | Uwe Langsenlehner, Petra Eder, Tanja Langsenlehner, S. Krenn-Pilko, Wilfried Renner |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_treatment Apoptosis Kaplan-Meier Estimate Strahlentherapie Onkogen Androgen deprivation therapy Prostate cancer 0302 clinical medicine Genotype Homozygote Hazard ratio Radiotherapy Dosage Middle Aged Combined Modality Therapy Neoadjuvant Therapy Proto-Oncogene Proteins c-bcl-2 030220 oncology & carcinogenesis Original Article medicine.medical_specialty Polymorphism Single Nucleotide 03 medical and health sciences Internal medicine Genetics medicine Humans Radiology Nuclear Medicine and imaging Polymorphism Genetik Alleles Oncogene Aged Neoplasm Staging Proportional Hazards Models Radiotherapy Apoptose business.industry Proportional hazards model Radiotherapy Planning Computer-Assisted Prostatic Neoplasms Androgen Antagonists medicine.disease Survival Analysis Confidence interval Polymorphismus Radiation therapy 030104 developmental biology Neoplasm Grading Radiotherapy Conformal business Follow-Up Studies |
| Zdroj: | Strahlentherapie Und Onkologie |
| ISSN: | 1439-099X 0179-7158 |
| DOI: | 10.1007/s00066-017-1126-9 |
| Popis: | Purpose The antiapoptotic B‑cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality. Methods The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients. Results During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10–4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58–3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05–3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51–3.36; p < 0.001). Conclusion This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink